ライフサイエンスコーパス: hyperlipidaemia

1 ducing the population burden associated with hyperlipidaemia.

2 tentiate the adverse effects of postprandial hyperlipidaemia.

3 verweight, insulin resistance, diabetes, and hyperlipidaemia.

4 hand osteoarthritis (HOA) could be linked to hyperlipidaemia.

5 uch as type-2 diabetes and familial combined hyperlipidaemia.

6 ar risk factors, especially hypertension and hyperlipidaemia.

7 ere proteinuria, hypoalbuminaemia, edema and hyperlipidaemia.

8 ting for the treatment of conditions such as hyperlipidaemia.

9 esity, hyperinsulinaemia, hyperglycaemia and hyperlipidaemia.

10 te cytoplasmic neutral lipid vesicles during hyperlipidaemia.

11 L receptor, a major determinant of inherited hyperlipidaemias.

12 Among controls 13% had untreated hyperlipidaemia, 11% were prescribed statins, 7% other L

13 hey may determine the degree of postprandial hyperlipidaemia, a known risk factor for the development

14 We find that early intermittent hyperlipidaemia alters the number and homeostatic phenot

15 l1(-/-)Apoe(-/-) and Apoe(-/-)mice decreases hyperlipidaemia and atherosclerosis.

16 s that includes obesity, insulin resistance, hyperlipidaemia and cardiovascular disease.

17 yndromes, type 2 diabetes, obesity, combined hyperlipidaemia and essential hypertension, are complex

18 oxidized lipids is an important link between hyperlipidaemia and fatty streak formation.

19 IV-1 have been linked with increased risk of hyperlipidaemia and hyperglycaemia.

20 Hyperlipidaemia and inflammation jointly contribute to a

21 sis and are widely used for the treatment of hyperlipidaemia and ischaemic heart disease.

22 a powerful therapeutic avenue to ameliorate hyperlipidaemia and protect from atherosclerosis.

23 idence for gross phenotypes such as obesity, hyperlipidaemia and type 2 diabetes.

24 proaches to understanding diabetes mellitus, hyperlipidaemias and heart disease in the general popula

25 ty-acid metabolism, with insulin resistance, hyperlipidaemia, and atherosclerosis as target diseases.

26 ed glucose tolerance and new-onset diabetes, hyperlipidaemia, and cardiovascular disease.

27 el-adjusted for smoking, sex, age, diabetes, hyperlipidaemia, and hypertension-hazard ratio 6.5, 0.9-

28 haemic heart disease, obesity, hypertension, hyperlipidaemia, and non-insulin-dependent diabetes mell

29 duals with a clinical diagnosis of untreated hyperlipidaemia; and a randomly selected group of other

30 plain the genetic basis of familial combined hyperlipidaemia, another familial lipid disorder in whic

31 of triglyceride-rich lipoproteins, and their hyperlipidaemia becomes progressively more severe with a

32 by the two diseases, including hypertension, hyperlipidaemia, diabetes mellitus, obesity, smoking, di

33 of body mass index, age, sex, hypertension, hyperlipidaemia, diabetes or smoking on change in EATv o

34 yocardial infarction were similar, with age, hyperlipidaemia, diabetes, abnormal renal function, and

35 ighting the importance of optimal control of hyperlipidaemia early in life, and providing insights in

36 conventional risk factors (eg, hypertension, hyperlipidaemia, excessive alcohol intake, smoking, obes

37 Familial combined hyperlipidaemia (FCHL) is a common, multifactorial disor

38 We mapped the hyperlipidaemia gene (Hyplip1) to the distal portion of

39 x (HR 2.68, 95% CI 1.06 to 6.83), history of hyperlipidaemia (HR 2.91, 95% CI 1.08 to 7.84) and early

40 such as obesity, polycystic ovarian disease, hyperlipidaemia, hypertension and atherosclerosis.

41 entional cardiovascular risk factors such as hyperlipidaemia, hypertension, and diabetes are common i

42 The key risk factors were hyperlipidaemia, hypertension, and elevated body mass in

43 latter effect being of possible relevance to hyperlipidaemia in type 2 diabetes mellitus.

44 entary lifestyle: weight gain, hypertension, hyperlipidaemia, insulin resistance, coronary artery dis

45 Hyperlipidaemia is a major risk factor of atheroscleroti

46 Inflammation and hyperlipidaemia jointly contribute to atherothrombotic d

47 dy mass index for individuals with untreated hyperlipidaemia (odds ratio 0.72 [95% CI 0.45-1.14]), or

48 aim was to examine the functional effect of hyperlipidaemia on blood monocytes.

49 These data demonstrate distinct effects of hyperlipidaemia on the chemotaxis and cytoskeletal regul

50 compared with people who had no diagnosis of hyperlipidaemia or exposure to other lipid-lowering drug

51 ribed statins, 7% other LLAs, and 69% had no hyperlipidaemia or LLA exposure.

52 the underlying metabolic defects in primary hyperlipidaemia or to define the impact of diseases such

53 ignificantly higher prevalence of history of hyperlipidaemia (OR = 3.83, p = 0.029), high-risk plaque

54 dent of the presence or absence of untreated hyperlipidaemia, or exposure to nonstatin LLAs.

55 c effects (hypersensitivity to asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated

56 tes [p<0.0001], hypertension [p<0.0001], and hyperlipidaemia [p<0.0001]) or cardiovascular disease at

57 ely to have hypertension, diabetes mellitus, hyperlipidaemia, prior stroke, lacunes, deep microbleeds

58 n E, lipid peroxidation and liver enzymes in hyperlipidaemia rabbits were investigated.

59 It is likely that the hyperlipidaemia results from a mutation of a novel gene

60 ce interval, 0.69-0.97, respectively), while hyperlipidaemia showed no significant effect (incidence

61 sex, ethnicity, geographic region, smoking, hyperlipidaemia, statin use, and blood pressure medicati

62 artery disease, blood pressure, diabetes, or hyperlipidaemia, suggesting that this locus is specific

63 ption, uncontrolled high blood pressure, and hyperlipidaemia--that can be effectively addressed for i

64 e relative contributions of inflammation and hyperlipidaemia to the risk of future cardiovascular eve

65 ion, myocardial infarction, stroke, obesity, hyperlipidaemia, type 2 diabetes mellitus and chronic ki

66 Although hyperlipidaemia was not reduced in treated animals, end-

67 is is reproduced by either hyperglycaemia or hyperlipidaemia, which also increase tissue levels of UD

68 associated with hypertension, diabetes, and hyperlipidaemia, while cardioembolic strokes were associ